How many investments has Heran Partners made?

Heran Partners has 17 tracked investments, 2 of which have exited via acquisition or IPO, including 2 dated in the last 24 months.

What stage does Heran Partners invest at?

Heran Partners invests at the Seed, Series A, Series B stages.

Where is Heran Partners located?

Heran Partners is headquartered in Antwerp, BE.

Who does Heran Partners co-invest with?

Heran Partners most often shares deals with ARCH Venture Partners, Capricorn Venture Partners, Korys, among 24 tracked co-investors.

Heran Partners

Venture capitaloperating company · company profile

Antwerp · Seed–Series B · 12 people tracked

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

Heran Partners backs enabling technologies in healthcare and life sciences that address unmet market needs, whether hardware, software, services or combinations. It targets innovations that improve patient treatment and care, generate actionable insights, or create efficiency gains across drug development and the patient journey. The firm's approach is grounded in macro trends such as an aging global population, the burden of chronic disease, and rising healthcare costs that make data and value-based care essential. It invests in companies demonstrating feasibility to bring disruptive innovation to market, at seed, Series A and Series B stages, tailoring investments for efficient value creation. It also provides mentorship, hands-on support and operational expertise, aiming to combine financial returns with societal impact.

Invests inBiotech Digital Health Healthtech Impact & Social Good Medical Devices Antwerp Belgium Europe Global United Kingdom

Source: firm website, verified Aug 3, 2026.

Stage

Seed–Series B

Antwerp, BE

Instruments

Equity

Founded

2019

Last 12 months

2 investments

AUM

$48.6M

Tracked investments

Team · 12 people

from the firm's website & public directories

Annie Vereecken· Founding Partner and Senior Advisor· Antwerp, Flemish Region, Belgiumin

Annie Vereecken is a Founding Partner and Senior Advisor at HERAN, where she advises on scientific and technological innovations under review. She founded Opdorp Finance, a family office pursuing a diversified strategy across asset management, private equity, real estate, and direct investments, and previously built the laboratory group Medhold, which was acquired by Sonic Healthcare in 2010. She holds a Master's in Pharmacy and a training degree in Clinical Pathology from KU Leuven.

a•••@heranpartners.comreveal

Herman Verrelst· Founding Partner & Senior Advisor· Leuven, Flemish Region, Belgiumin

Herman Verrelst is a serial entrepreneur with over 25 years in high-tech companies. He founded and exited several University of Leuven spin-offs, including Cartagenia, which was acquired by Agilent, after which he led Agilent's Genomics & Clinical Applications division in California. He later served as CEO of Biocartis, a molecular diagnostics company focused on personalized medicine.

h•••@heranpartners.comreveal

Joris Mortelmans· Partner & Senior Advisor· Zoersel, Flemish Region, Belgiumin

Joris Mortelmans advises HERAN on financial matters and fund operations, and serves as CEO of Opdorp Finance, the family office of Annie Vereecken. He previously worked as CFO of Laboratoria Wolfs, Finance Director at Euphony, and as an auditor at EY, gaining experience in healthcare, M&A, and fundraising. He holds a Master's degree in Applied Economics from the University of Antwerp.

j•••@heranpartners.comreveal

Katleen Vandersmissen· Managing Partner· Antwerp Metropolitan Areain

Katleen Vandersmissen is Managing Partner at HERAN Partners, a venture capital firm focused on European HealthTech. Her background spans industry, management consultancy, and the venture capital and private equity sectors, with experience across life sciences, technology, and recycling and materials. Her areas of expertise include strategic and business planning, execution, negotiations, people management, and coaching.

k•••@heranpartners.comreveal

Mercedes Tuin· Partner· Netherlandsin

m•••@heranpartners.comreveal

Raf Roelands· Partner· Brussels Region, Belgiumin

Raf Roelands has around ten years of operational experience in biotech. He holds an M.Sc. in Biochemistry and Biotechnology and an MBA from Vlerick Business School, along with postgraduate certificates from Guberna. Before joining HERAN, he spent over five years at Korys working on life science investments and advised European and US-based investment funds.

r•••@heranpartners.comreveal

Geoffrey D'hondt· Investment Directorin

g•••@heranpartners.comreveal

Emke Goijens· Operations & Communications· Antwerp Metropolitan Areain

Emke Goijens is the Operations & Communications Lead at HERAN Partners, a Belgian HealthTech and MedTech investment fund. Her responsibilities include designing business processes, leading cross-functional projects, and overseeing communication and marketing efforts, as well as coordinating events for executives and investors. She supports the Managing Partner with calendar management and annual planning, and works with the Finance Director on fund administration and compliance; she speaks Dutch, English, and French.

e•••@heranpartners.comreveal

Flore Belmans· Investment Team· Leuven, Flemish Region, Belgiumin

Flore Belmans joined Heran in May 2026 as part of the investment team, where she works on deal flow screening and assessment, due diligence, market analysis, and technological evaluation. She holds a BSc in Bioscience Engineering and an MSc in Biomedical Engineering from KU Leuven and pursued a PhD there developing AI-powered imaging biomarkers for pulmonary disease. She also worked as a Research Scientist at radiomics.bio, with expertise spanning AI, medical imaging, and healthcare.

f•••@heranpartners.comreveal

Margot Huysmans· Analyst· Belgiumin

Margot Huysmans joined HERAN Partners in April 2025 after completing an internship at the firm, working at the intersection of life sciences and venture capital. On the investment team, she works on deal flow screening and assessment, and due diligence including market analysis and technical evaluation. She holds an MSc in Bioscience Engineering (Cellular and Genetic Engineering) from KU Leuven and an MSc in Entrepreneurship and Innovation from Lund University, where she also worked on her own startup, Stride.

m•••@heranpartners.comreveal

Wim Van Looveren· Finance and Administration (Finance Director)· Antwerp, Flemish Region, Belgiumin

Wim Van Looveren joined HERAN in February 2024, where he handles finance and administrative matters for the fund and the GP and supports portfolio companies on finance topics. He previously worked for 3 years as Finance Director at Astanor Ventures and spent 11 years in various roles at Incofin Investment Management. He holds a Master's degree in Applied Economic Sciences and in International Relations & Diplomacy from the University of Antwerp.

Laurens de Vries· Analyst

l•••@heranpartners.comreveal

What they invest in

from 14 of 17 portfolio companies

AI & Machine Learning ×10Biotech ×7Healthtech ×6Deep Tech ×4Digital Health ×4Medical Devices ×4Data & Infrastructure ×3Hardware ×2

HQs:Belgium×3Spain×1United States×1

Investments · 17 tracked

founders shown can be your intro path

By year:2026 · 1 2025 · 12 dated

Amaronamaron.be in

Amaron provides solutions for unlocking and integrating medical data, using standards-based interoperability protocols such as HL7 FHIR, HL7v2, DICOM, XDS, OMOP, and OpenEHR.

Data & InfrastructureDigital HealthHealthtech

Aspect Analyticsaspect-analytics.com inSep 2025

Aspect Analytics develops Weave, software that aligns and analyzes spatial and molecular data (spatial transcriptomics, proteomics, metabolomics, mass spectrometry imaging, and histology) at single-cell precision to study cellular neighborhoods and tissue architecture.

AI & Machine LearningBiotechSaaS

Co-investorsCapricorn Venture Partners PMV

Broken String Biosciencesbrokenstringbio.com in

Broken String Biosciences develops tools for genome-wide on- and off-target analysis in gene editing, enabling in-house detection and characterization of gene editing-induced DNA breaks.

AI & Machine LearningBiotechDeep Tech

Co-investorsFirst In Ventures Illumina Ventures Korys Mérieux Equity Partners

Fluidicfluidic.com in 𝕏

Fluidic develops biophysics and single-cell analysis tools, including Fluidity One-M for in-solution protein interaction analysis using Microfluidic Diffusional Sizing and the Cyto-Mine platform for high-throughput single-cell screening via picodroplet microfluidics.

BiotechDeep TechHardware

James Wilkinsonin

Co-investorsCambridge Innovation Capital Draper Esprit

Gynaiagynaia.com

Gynaia provides training, certification, quality assessment, and clinical decision support tools for gynecological ultrasound professionals, including an LMS, curated clinical case database, live case webinars, and diagnostic apps such as the ADNEX model.

AI & Machine LearningDigital HealthEdTechFemTech

Hypervision Surgicalhypervisionsurgical.com in 𝕏Apr 2026

Hypervision Surgical develops an intraoperative hyperspectral imaging system that uses AI to provide real-time, contrast-free tissue characterisation during surgery.

AI & Machine LearningHealthtechMedical Devices

Co-investorsHeal Capital LifeX Ventures Meridian Health Ventures Sonorcap Angelini Ventures redalpine +1 more

Icometrixicometrix.com in 𝕏

icometrix develops FDA-cleared, CE-marked AI software (icobrain) that quantifies and compares brain MRI scans over time to support radiologists and neurologists in diagnosing and monitoring neurological conditions such as multiple sclerosis and Alzheimer's disease.

AI & Machine LearningDigital HealthMedical DevicesLeuven, BE

Co-investorsCapricorn Venture Partners Forestay Capital Optum Ventures

IDbyDNAillumina.comAcquired

Scalable, high throughput DNA sequencing platforms.

Co-investorsARCH Venture Partners Artis Ventures Hemisphere Ventures LLC SPRINGROCK VENTURES Venrock

Immunespecimmunespec.com

ImmuneSpec provides immunopeptidomics (MHC-associated peptide proteomics, MAPPs) analysis services used to identify T cell epitopes and assess the immunogenicity risk of biotherapeutics.

BiotechDeep TechHealthtech

Lynxlynx.care in

LynxCare provides EHR-derived real-world data and evidence for medical and clinical research, using a federated hospital network, clinical NLP enrichment, and the OMOP Common Data Model.

AI & Machine LearningData & InfrastructureHealthtech

Co-investorsMatterwave Ventures Elaia Flare Capital Partners

Nuclivisionnuclivision.com in

NucliVision develops technology for nuclear medicine departments to address capacity constraints amid rising demand in theranostics, neurology, and cardiology.

AI & Machine LearningHealthtechMedical Devices

Co-investorsimec.istart

Ontoforceontoforce.com in 𝕏

ONTOFORCE builds DISQOVER, a life sciences-specific semantic layer that unifies proprietary, licensed, and public biomedical datasets into an ontology-based knowledge graph queryable in natural language.

AI & Machine LearningBiotechData & Infrastructure

Co-investorsKorys

Pharmacelerapharmacelera.com in 𝕏

Pharmacelera develops computational chemistry software and services for drug discovery, using proprietary 3D molecular field descriptors, quantum mechanics, and AI to screen ultra-large chemical libraries and identify novel, synthesizable compounds.

AI & Machine LearningBiotechDeep TechBarcelona, ES

Enric Gibert(Founder)Enric Herrero(Founder)

Co-investorsCapital Cell GENERAL INCEPTION

Thermo Fisher Scientificthermofisher.com in 𝕏Acquired

Thermo Fisher provides life science products and laboratory equipment, including antibodies, consumables, biobanking resources, and Cryo-EM imaging systems for research labs and scientists.

BiotechEnterprise SoftwareHardwareHealthtechWaltham, US

Marc N. Casper(Executive Officer, Director)Andrew J. Thomson(Executive Officer)William G. Parrett(Director)Peter M. Wilver(Executive Officer)Seth H. Hoogasian(Executive Officer)Alan J. Malus(Executive Officer)

Co-investorsARCH Venture Partners BayMed Venture Partners Cross Creek Advisors Excel Venture Management Oak HC/FT Domain Associates +1 more

Thironathirona.eu in

Thirona develops AI-powered lung image analysis technology, centered on its modular LungQ platform for segmentation and quantification of lung structures and disease from CT and other imaging.

AI & Machine LearningDigital HealthMedical Devices

Co-investorsBorski Fund

Ugentecugentec.com

Vixenbiovixenbio.com

Portfolio news

latest coverage across their companies

Why value of Wolves, Lynx has skyrocketed to $4.5 billion — and why investors still see upside

Lynx · startribune.com · Aug 23, 2026

Earnings call transcript: Amara Raja Batteries beats Q1 2026 EPS, shares rise 8% By Investing.com

Amaron · au.investing.com · Aug 11, 2026

Hypervision Surgical Raises £17M in Series A Funding

Hypervision Surgical · finsmes.com · Apr 29, 2026

Pharmacelera raises $6m to advance AI drug discovery - Drug Discovery World (DDW)

Pharmacelera · ddw-online.com · Feb 20, 2026

Belgian Spatial Biology Bioinformatics Firm Aspect Analytics Raises €10M | GenomeWeb

Aspect Analytics · genomeweb.com · Sep 9, 2025

Ghent start-up Nuclivision uses AI-driven imaging to make PET scans safer

Nuclivision · belganewsagency.eu · Jul 16, 2025

Gynaia Raises $2.5 Million in Seed Funding to Transform Women’s Health Diagnostics

Gynaia · gynaia.com · May 22, 2025

Frequently asked questions

How many investments has Heran Partners made?: Heran Partners has 17 tracked investments, 2 of which have exited via acquisition or IPO, including 2 dated in the last 24 months.
What stage does Heran Partners invest at?: Heran Partners invests at the Seed, Series A, Series B stages.
What sectors does Heran Partners focus on?: Heran Partners focuses on Biotech, Digital Health, Healthtech, Impact & Social Good, Medical Devices.
Where is Heran Partners located?: Heran Partners is headquartered in Antwerp, BE.
Who does Heran Partners co-invest with?: Heran Partners most often shares deals with ARCH Venture Partners, Capricorn Venture Partners, Korys, among 24 tracked co-investors.

Images

Similar investors

Lerer Hippeau

Lerer Hippeau is an early-stage venture capital firm that backs founders across sectors, emphasizing investing in companies before they gain wider recognition.

$500K – $2M

Cancer Fund

Cancer Fund is an early-stage oncology venture capital and venture-giving organization that funds diagnostics, therapeutics, and other cancer-targeting innovations, offering both charitable donation and accredited-investor pathways.

Novo Holdings

Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.

$1.1M – $54M

MDI Ventures

MDI Ventures is the corporate venture capital arm of Telkom Indonesia, investing in and building synergies between technology startups and Indonesian enterprises. It manages a multi-fund platform (including Centauri Fund, Arise, and sector-specific funds) with a portfolio of 80+ companies.

$500K – $75M

Asabys Partners

Asabys Partners is a healthcare and life sciences venture capital firm that invests in innovative science and medical technologies to improve patients' lives.